Healthcare of Ontario Pension Plan Trust Fund Has $9.18 Million Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Healthcare of Ontario Pension Plan Trust Fund reduced its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 5.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 498,500 shares of the company’s stock after selling 29,642 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund owned about 0.23% of Hims & Hers Health worth $9,182,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. Renaissance Technologies LLC lifted its stake in Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after buying an additional 3,205,108 shares in the last quarter. State of Michigan Retirement System boosted its stake in Hims & Hers Health by 177.8% in the 2nd quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock worth $10,095,000 after purchasing an additional 320,000 shares during the period. Carnegie Investment Counsel bought a new position in Hims & Hers Health during the 3rd quarter worth about $5,531,000. Bank of New York Mellon Corp raised its stake in shares of Hims & Hers Health by 67.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock valued at $13,701,000 after purchasing an additional 273,473 shares during the period. Finally, Panagora Asset Management Inc. lifted its holdings in shares of Hims & Hers Health by 246.2% in the second quarter. Panagora Asset Management Inc. now owns 378,192 shares of the company’s stock valued at $7,636,000 after purchasing an additional 268,949 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $32.22 on Friday. Hims & Hers Health, Inc. has a 1 year low of $8.09 and a 1 year high of $35.02. The company has a 50 day simple moving average of $22.01 and a 200 day simple moving average of $19.86. The firm has a market cap of $7.04 billion, a PE ratio of 73.23 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same period in the prior year, the company posted ($0.04) earnings per share. Hims & Hers Health’s revenue for the quarter was up 77.1% compared to the same quarter last year. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $487,789.12. This trade represents a 84.94 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Oluyemi Okupe sold 142,886 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.93, for a total transaction of $4,276,577.98. Following the sale, the chief financial officer now owns 112,186 shares of the company’s stock, valued at $3,357,726.98. This trade represents a 56.02 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,153,519 shares of company stock worth $24,486,721. 17.71% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft increased their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Canaccord Genuity Group lifted their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their target price for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Piper Sandler reiterated a “neutral” rating and issued a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Finally, Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective for the company. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $20.71.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.